Methylprednisolone treatment in acute spinal cord injury: the myth challenged through a structured analysis of published literature

Spine Journal

Volumn 6, Issue 3, 2006, Pages 335-343

  Sayer, Faisal T ^a   Kronvall, Erik ^a   Nilsson, Ola G ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Methylprednisolone; NASCIS; National Acute Spinal Cord Injury Study; Secondary injury; Spinal cord injury; Spine trauma

Indexed keywords

METHYLPREDNISOLONE; NALOXONE; PLACEBO; TIRILAZAD;

ACUTE DISEASE; ANALYTIC METHOD; ARTIFACT; AVASCULAR NECROSIS; CLINICAL TRIAL; CONVALESCENCE; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; MEDICAL LITERATURE; NONHUMAN; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLICATION; RESPIRATORY TRACT DISEASE; REVIEW; SEPSIS; SPINAL CORD INJURY; STANDARD; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; HUMANS; METHYLPREDNISOLONE; RECOVERY OF FUNCTION; SPINAL CORD INJURIES;

EID: 33646050607     PISSN: 15299430     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spinee.2005.11.001     Document Type: Review

References (60)

1. De Vivo M.J. Causes and cost of spinal cord injury in the United States. Spinal Cord 35 (1997) 809-813
2. Vellacott P.N., and Webb-Johnson A.E. Lancet i (1919) 173
3. Frankel H.L., Coll J.R., Charlifue S.W., et al. Long-term survival in spinal cord injury: a fifty year investigation. Spinal Cord 36 (1998) 266-274
4. Yeo J.D., Walsh J., Rutkowski S., Soden R., Craven M., and Middleton J. Mortality following spinal cord injury. Spinal Cord 36 (1998) 329-336
5. McColl M.A., Walker J., Stirling P., Wilkins R., and Corey P. Expectations of life and health among spinal cord injured adults. Spinal Cord 35 (1997) 818-828
6. Kakulas B.A. The clinical neuropathology of spinal cord injury: a guide to the future. Paraplegia 25 (1987) 212-216
7. Bunge R.P., Puckett W.R., Becerra J.L., Marcillo A., and Quencer R.M. Observations on the pathology of human spinal cord injury: a review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. Adv Neurol 59 (1993) 75-89
8. Dusart I., and Schwab M.E. Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur J Neurosci 6 (1994) 712-724
9. Tator C.H. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol 5 (1995) 407-413
10. Faden A.I. Experimental neurobiology of central nervous system trauma. Crit Rev Neurobiol 7 (1993) 175-186
11. Taoka Y., and Okajima K. Role of leukocytes in spinal cord injury in rats. J Neurotrauma 17 (2000) 219-229
12. Blight A.R. Morphometric analysis of blood vessels in chronic experimental spinal cord injury: hypervascularity and recovery of function. J Neurol Sci 106 (1991) 158-174
13. Amar A.P., and Levy M.L. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 44 (1999) 1027-1039
14. Sypert G.W. Thoracolumbar fusion techniques. Clin Neurosurg 36 (1990) 186-216
15. Geisler F.H., Dorsey F.C., and Coleman W.P. Past and current clinical studies with GM-1 ganglioside in acute spinal cord injury. Ann Emerg Med 22 (1993) 1041-1047
16. Olsson Y., Sharma H.S., Nyberg F., and Westman J. The opioid receptor antagonist naloxone influences the pathophysiology of spinal cord injury. Prog Brain Res 104 (1995) 381-399
17. Zeidman S.M., Ling G.S., Ducker T.B., and Ellenogen R.G. Clinical applications of pharmacologic therapies for spinal cord injury: past and current clinical studies with GM-1 ganglioside in acute spinal cord injury. J Spinal Disord 9 (1996) 367-380
18. Geisler F.H., Dorsey F.C., and Coleman W.P. Recovery of motor function after spinal cord injury: a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 324 (1991) 1829-1839
19. Geisler F.H. GM-1 ganglioside and motor recovery following human spinal cord injury. J Emerg Med 11 (1993) 49-55
20. Geisler F.H. Clinical trials of pharmacotherapy for spinal cord injury. Ann NY Acad Sci 845 (1998) 374-381
21. Clark W.M., Hazel J.S., and Coull B.M. Lazaroids: CNS pharmacology and current research. Drugs 50 (1995) 971-983
22. Bracken M.B., Shepard M.J., Holford T.R., et al. Administration of methylprednisolone for 24 or 48 hours or tirilazade mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA 277 (1997) 1597-1604
23. Petitjean M.E., Pointillart V., Dixmerias F., et al. Traitement medicamenteux de la lesion medullaire traumatique au stade aigu. Ann Fr Anesth Reanim 17 (1998) 114-122
24. Segal J.L., Pathak M.S., Hernandez J.P., Himer P.L., Brunnemann S.R., and Charter R.S. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. Pharmacotherapy 19 (1999) 713-723
25. Stein R.B. Functional electrical stimulation after spinal cord injury. J Neurotrauma 16 (1999) 713-717
26. Grijalva I., Guizar-Sahagun G., Castaneda-Hernandez G., et al. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial. Pharmacotherapy 23 (2003) 823-834
27. Bracken M.B., Shepard M.J., Collins W.F., et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data: results of the Second National Acute Spinal Cord Injury Study. J Neurosurg 76 (1992) 23-31
28. Bracken M.B., and Holford T.R. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J Neurosurg 79 (1993) 500-507
29. Bracken M.B., Shepard M.J., Holford T.R., et al. Methylprednisolone or tirilazade mesylate administration after acute spinal cord injury: 1-year follow-up data: results of the third National Acute Spinal Cord Injury randomized controlled trial. J Neurosurg 89 (1998) 699-706
30. Faden A.I., Jacobs T.P., Smith M.T., and Zivin J.A. Naloxone in experimental spinal cord ischemia: dose-response studies. Eur J Pharm 103 (1984) 115-120
31. Ross I.B., and Tator C.H. Spinal cord blood flow and evoked potential responses after treatment with nimodipine or methylprednisolone in spinal cord-injured rats. Neurosurgery 33 (1993) 470-476
32. Ross I.B., Tator C.H., and Theriault E. Effect of nimodipine or methylprednisolone on recovery from acute experimental spinal cord injury in rats. Surg Neurol 40 (1993) 461-470
33. Koyanagi I., and Tator C.H. Effect of a single huge dose of methylprednisolone on blood flow, evoked potentials, and histology after acute spinal cord injury in the rat. Neurol Res 19 (1997) 289-299
34. Short D.J., El Masry W.S., and Jones P.W. High dose methylprednisolone in the management of acute spinal cord injury: a systematic review from a clinical perspective. Spinal Cord 38 (2000) 273-286
35. Coleman W.P., Benzel E., Cahill D.W., et al. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord 13 (2000) 185-199
36. Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery 50 Suppl. 3 (2002) 63-72
37. Peter Vellman W., Hawkes A.P., and Lammertse D.P. Administration of corticosteroids for acute spinal cord injury: the current practice of trauma medical directors and emergency medical system physician advisors. Spine 28 (2003) 941-977
38. Hurlbert R.J. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg (Spine) 93 (2000) 1-7
39. Bracken M.B., Shepard M.J., Hellenbrand K.G., et al. Methylprednisolone and neurological function 1 year after spinal cord injury: results of the National Acute Spinal Cord Injury Study. J Neurosurgery 63 (1985) 704-713
40. Bracken M.B., Shepard M.J., Collins W.F., et al. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322 (1990) 1405-1411
41. Nesathurai S. Steroids and spinal cord injury: revisiting the NASCIS 2 and NASCIS 3 trials. J Trauma 45 (1998) 1088-1093
42. Young W., and Bracken M.B. The Second National Acute Spinal Cord Injury Study. J Neurotrauma 9 Suppl. 1 (1992) S397-S405
43. Shepard M.J., and Bracken M.B. The effect of methylprednisolone, naloxone, and spinal cord trauma on four liver enzymes: observations from NASCIS 2. National Acute Spinal Cord Injury Study. Paraplegia 32 (1994) 236-245
44. Bracken M.B. Cochrane Database Syst Rev 2 (2000) CD001046
45. Ducker T.B., and Zeidman S.M. Spinal cord injury: role of steroid therapy. Spine 19 (1994) 2281-2287
46. Pointillart V., Petitjean M.E., Wiart L., et al. Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 38 (2000) 71-76
47. Acland R.H., Anthony A., Inglis G.S., Walton D.I., and Xiong X. Methylprednisolone use in acute spinal cord injury. N Z Med J 114 (2001) 99
48. Galandiuk S., Raque G., Appel S., and Polk H.C. The two-edged sword of large-dose steroids for spinal cord trauma. Ann Surg 218 (1993) 419-427
49. Gerhart K.A., Johnson R.L., Menconi J., Hoffman R.E., and Lammertse D.P. Utilization and effectiveness of methylprednisolone in a population-based sample of spinal cord injured persons. Paraplegia 33 (1995) 316-321
50. George E.R., Scholten D.J., Buechler C.M., Jordan-Tibbs J., Mattice C., and Albrecht R.M. Failure of methylprednisolone to improve the outcome of spinal cord injuries. Am Surg 61 (1995) 659-663
51. Gerndt S.J., Rodriguez J.L., Pawlik J.W., et al. Consequences of high-dose steroid therapy for acute spinal cord injury. J Trauma 42 (1997) 279-284
52. Poynton A.R., O'Farrell D.A., Shannon F., Murray P., McManus F., and Walsh M.G. An evaluation of the factors affecting neurological recovery following spinal cord injury. Injury 28 (1997) 545-548
53. Prendergast M.R., Saxe J.M., Ledgerwood A.M., Lucas C.E., and Lucas W.F. Massive steroids do not reduce the zone of injury after penetrating spinal cord injury. J Trauma 37 (1994) 576-579
54. Levy M.L., Gans W., Wijesinghe H.S., SooHoo W.E., Adkins R.H., and Stillerman C.B. Use of methylprednisolone as an adjunct in the management of patients with penetrating spinal cord injury: outcome analysis. Neurosurgery 39 (1996) 1141-1148
55. Koc R.K., Akdemir H., Karakücük E.I., Ökem I.S., and Menkü A. Effect of methylprednisolone, tirilazad mesylate and vitamin E on lipid peroxidation after experimental spinal cord injury. Spinal Cord 37 (1999) 29-32
56. Matsumoto T., Tamaki T., Kawakami M., Yoshida M., Ando M., and Yamada H. Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine 26 (2001) 426-430
57. Hayashi M., Ueyama T., Tamaki T., and Senba E. Expression of neurotrophin and IL-1 beta mRNAs following spinal cord injury and the effects of methylprednisolone treatment. Kaibogaku Zasshi 72 (1997) 209-213
58. Kell T.A. The role of the immune system in central nervous system regeneration (theoretical considerations). Med Hypothesis 26 (1988) 13-15
59. Wing P.C., Nance P., Connell D.G., and Gagnon F. Risk of avascular necrosis following short-term megadose methylprednisolone treatment. Spinal Cord 36 (1998) 633-636
60. Hugenholtz H. Methylprednisolone for acute spinal cord injury: not a standard of care. CMAJ 168 (2003) 1145-1146